
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.
See what she has to say







